Impact of substance dependence and dual diagnosis on the quality of life of heroin users seeking treatment

Mònica Astals; Antònia Domingo-Salvany; Claudio Castillo Buenaventura; Jordi Tato; José Ma Vazquez; Rocío Martín-Santos; Marta Torrens

doi:10.1080/10826080701204813

Impact of substance dependence and dual diagnosis on the quality of life of heroin users seeking treatment

Mònica Astals, Antònia Domingo-Salvany, Claudio Castillo Buenaventura, Jordi Tato, José Ma Vazquez, Rocío Martín-Santos, Marta Torrens

Department of Psychiatry and Legal Medicine

Research output: Contribution to journal › Article › Research › peer-review

69 Citations (Scopus)

Abstract

In 189 opioid-dependent subjects on methadone maintenance treatment in Barcelona (Spain), we assessed the prevalence of co-occurrence substance use and non-substance-use disorders (dual diagnosis) by the Psychiatric Research Interview for Substance and Mental Disorders [PRISM], and the impact on quality of life (HRQoL) by the SF-12 (PCS-12 and MCS-12 scales). Rates of substance and non-substance-use diagnoses were 59% and 32%, respectively. Mean scores for PCS-12 and MCS-12 were 44.1 ± 10.1 and 39.9 ± 11.7, without differences by presence or absence of dual diagnosis. Heroin users on methadone treatment showed a high prevalence of dual diagnosis and a very impaired HRQoL. Copyright © 2008 Informa Healthcare USA, Inc.

Original language	English
Pages (from-to)	612-632
Journal	Substance Use and Misuse
Volume	43
Issue number	5
DOIs	https://doi.org/10.1080/10826080701204813
Publication status	Published - 1 Jan 2008

Keywords

Dual diagnosis
Heroin dependence
Methadone
Psychiatric comorbidity
Quality of life

Access to Document

10.1080/10826080701204813

Cite this

@article{b3d20a4c655041f588d49b928a4a5726,

title = "Impact of substance dependence and dual diagnosis on the quality of life of heroin users seeking treatment",

abstract = "In 189 opioid-dependent subjects on methadone maintenance treatment in Barcelona (Spain), we assessed the prevalence of co-occurrence substance use and non-substance-use disorders (dual diagnosis) by the Psychiatric Research Interview for Substance and Mental Disorders [PRISM], and the impact on quality of life (HRQoL) by the SF-12 (PCS-12 and MCS-12 scales). Rates of substance and non-substance-use diagnoses were 59% and 32%, respectively. Mean scores for PCS-12 and MCS-12 were 44.1 ± 10.1 and 39.9 ± 11.7, without differences by presence or absence of dual diagnosis. Heroin users on methadone treatment showed a high prevalence of dual diagnosis and a very impaired HRQoL. Copyright {\textcopyright} 2008 Informa Healthcare USA, Inc.",

keywords = "Dual diagnosis, Heroin dependence, Methadone, Psychiatric comorbidity, Quality of life",

author = "M{\`o}nica Astals and Ant{\`o}nia Domingo-Salvany and Buenaventura, {Claudio Castillo} and Jordi Tato and Vazquez, {Jos{\'e} Ma} and Roc{\'i}o Mart{\'i}n-Santos and Marta Torrens",

year = "2008",

month = jan,

day = "1",

doi = "10.1080/10826080701204813",

language = "English",

volume = "43",

pages = "612--632",

journal = "Substance Use and Misuse",

issn = "1082-6084",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Impact of substance dependence and dual diagnosis on the quality of life of heroin users seeking treatment

AU - Astals, Mònica

AU - Domingo-Salvany, Antònia

AU - Buenaventura, Claudio Castillo

AU - Tato, Jordi

AU - Vazquez, José Ma

AU - Martín-Santos, Rocío

AU - Torrens, Marta

PY - 2008/1/1

Y1 - 2008/1/1

N2 - In 189 opioid-dependent subjects on methadone maintenance treatment in Barcelona (Spain), we assessed the prevalence of co-occurrence substance use and non-substance-use disorders (dual diagnosis) by the Psychiatric Research Interview for Substance and Mental Disorders [PRISM], and the impact on quality of life (HRQoL) by the SF-12 (PCS-12 and MCS-12 scales). Rates of substance and non-substance-use diagnoses were 59% and 32%, respectively. Mean scores for PCS-12 and MCS-12 were 44.1 ± 10.1 and 39.9 ± 11.7, without differences by presence or absence of dual diagnosis. Heroin users on methadone treatment showed a high prevalence of dual diagnosis and a very impaired HRQoL. Copyright © 2008 Informa Healthcare USA, Inc.

AB - In 189 opioid-dependent subjects on methadone maintenance treatment in Barcelona (Spain), we assessed the prevalence of co-occurrence substance use and non-substance-use disorders (dual diagnosis) by the Psychiatric Research Interview for Substance and Mental Disorders [PRISM], and the impact on quality of life (HRQoL) by the SF-12 (PCS-12 and MCS-12 scales). Rates of substance and non-substance-use diagnoses were 59% and 32%, respectively. Mean scores for PCS-12 and MCS-12 were 44.1 ± 10.1 and 39.9 ± 11.7, without differences by presence or absence of dual diagnosis. Heroin users on methadone treatment showed a high prevalence of dual diagnosis and a very impaired HRQoL. Copyright © 2008 Informa Healthcare USA, Inc.

KW - Dual diagnosis

KW - Heroin dependence

KW - Methadone

KW - Psychiatric comorbidity

KW - Quality of life

U2 - 10.1080/10826080701204813

DO - 10.1080/10826080701204813

M3 - Article

VL - 43

SP - 612

EP - 632

JO - Substance Use and Misuse

JF - Substance Use and Misuse

SN - 1082-6084

IS - 5

ER -

Impact of substance dependence and dual diagnosis on the quality of life of heroin users seeking treatment

Abstract

Keywords

Access to Document

Fingerprint

Cite this